[Comment] A new era for treatment development in HER2-positive breast cancer

HER2-positive breast cancer has long been considered a clinically distinct disease, mainly because of the striking efficacy achieved by HER2-targeted treatments in the early and metastatic settings. However, the effectiveness of these therapies has been variable, and the development of different types of treatment resistance reveals the diversity of HER2-positive breast cancers. As part of efforts by the International Cancer Genome Consortium (ICGC) Breast Cancer Working Group, Ferrari and colleagues1 established the gene expression profiles of HER2-positive breast tumours.

Source: The Lancet Oncology - January 8, 2018 Category: Cancer & Oncology Authors: Xavier Pivot, David G Cox Tags: Comment Source Type: research